Primary NK/T-cell lymphoma of the larynx.

Abstract

Laryngeal extranodal non-Hodgkin lymphoma is uncommon, accounting for less than 1% of all laryngeal neoplasms; the B-cell phenotype is predominant. Lymphomas outside the nasal cavity are rare and highly aggressive. We present a case of primary natural killer T-cell (NK/T-cell) lymphoma of the larynx that arose in a 45-year-old man. Because only a limited amount of data is available on laryngeal NK/T-cell lymphoma, the mainstay of treatment remains unclear, although some data suggest that radiotherapy alone is the best option. Our patient was treated with chemotherapy and radiotherapy, and he remained in remission 2 years later.

• Authors: Nechama Uri, Yaakov Schindler, Miriam Quitt, Olga Valkovsky, Geva Barzilai
• Journal: Ear, nose, & throat journal (Ear Nose Throat J) Vol. 91 Issue 5 Pg. 206-7 (May 2012) ISSN: 1942-7522 [Electronic] United States
• PMID: 22614556 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Carcinoma, Squamous Cell (diagnosis)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Head and Neck Neoplasms (diagnosis)
• Humans
• Laryngeal Neoplasms (drug therapy, pathology, radiotherapy)
• Lymphoma, Extranodal NK-T-Cell (drug therapy, pathology, radiotherapy)
• Male
• Middle Aged
• Prednisone (administration & dosage)
• Squamous Cell Carcinoma of Head and Neck
• Tomography, X-Ray Computed
• Vincristine (administration & dosage)
• Vocal Cords (pathology)